Back to Top

cMET

0 comments

Submitted by Annemieke DeMaggio on Tue, 08/25/2020 - 10:55

Tepotinib granted FDA priority review for METex14 NSCLC

FDA BTD and NDA filing based on data from ongoing phase 2 VISION study; no PDUFA date mentioned (EMD press release)